Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody

CD40-targeting therapies can enhance the dendritic cell priming of tumor-specific T cells and repolarize intratumoral macrophages to alleviate the tumoral immunosuppressive environment and remodel the extracellular matrix. Mitazalimab is a potent agonistic CD40 monoclonal IgG1 antibody currently und...

Descripción completa

Detalles Bibliográficos
Autores principales: Andersson, Hampus, Sobti, Aastha, Jimenez, David Gomez, de Coaña, Yago Pico, Ambarkhane, Sumeet Vijay, Hägerbrand, Karin, Smith, Karin Enell, Lindstedt, Malin, Ellmark, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572020/
https://www.ncbi.nlm.nih.gov/pubmed/37830579
http://dx.doi.org/10.3390/cells12192365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572020/
https://www.ncbi.nlm.nih.gov/pubmed/37830579
http://dx.doi.org/10.3390/cells12192365

Ejemplares similares